Molecular Health appoints Dr. Christian Meisel as corporate Chief Medical Officer (CMO).
Dr. Meisel comes to Molecular Health with over 25 years of experience in the healthcare sector – including clinical practice and research & development across academia and the biopharmaceutical industry – and more than 10 years in senior pharma leadership roles. As an MD and PhD with additional qualifications in computer science and extensive experience in precision medicine, Dr. Meisel will be responsible for all clinical aspects of Molecular Health’s portfolio and development. As a member of the company’s leadership, he will also provide strategic direction and leadership in the development of Molecular Health.
Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: ”We are very pleased to have Dr. Meisel join as our Chief Medical Officer. He not only is an experienced physician but, next to his background in computer science, also brings an extensive track record and expertise in precision medicine across the biopharmaceutical and diagnostics industry. With his broad experience in molecular diagnostics and drug development, he is a perfect addition to our development and commercial teams and will strategically enhance and further sharpen the focus of our offerings to pharma, physicians, providers, payers and the financial industry. The CMO position is key for our growth strategy, and we are happy to have found Christian for this important role at Molecular Health.”
Dr. Meisel adds: “I am very much looking forward to joining Molecular Health – a company at the forefront of the digital transformation of medicine and R&D – as a member of the executive team. I will bring my first-hand experience and deep knowledge of the demands of patients and healthcare providers to further improve Molecular Health’s innovative solutions to impact patient care, therapeutic and diagnostic product development, and meet the growing needs of the medical community in the digitalization of healthcare.”
Dr. Christian Meisel joins Molecular Health from Roche where he served for more than 14 years in numerous senior leadership roles, including Global Head Personalized Healthcare Platform, acting Global Head Translational Medicine Oncology, and Global Head Biomarkers and Translational R&D Innovation. Dr. Meisel is board-certified in Internal Medicine and in Clinical Pharmacology, holds an MD from the Technical University of Munich, and a PhD from Charité Berlin, where he also served as associate professor and leader of a bioinformatics research group.